<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03015038</url>
  </required_header>
  <id_info>
    <org_study_id>C16-21</org_study_id>
    <secondary_id>2016-A01102-49</secondary_id>
    <nct_id>NCT03015038</nct_id>
  </id_info>
  <brief_title>Study of the Immune Response in Colon Adenocarcinoma</brief_title>
  <acronym>IMCO</acronym>
  <official_title>Etude de la réponse Immunitaire Dans l'adénocarcinome Colique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duration of each part of the study per patient:

        -  Screening: From 1 to 4 weeks

        -  Sampling period (blood and tissue): 1 day

        -  Follow-up by patient: 60 months

        -  Total study duration by patient: 84 months

        -  Total inclusion duration: 24 months

        -  Total Follow-up duration: 60 months

        -  Total study duration: 84 months
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immune cells trafficking</measure>
    <time_frame>Day 0</time_frame>
    <description>Frequency of T cells in the blood and tissue (Flow cytometry method with a panel of Ab).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infiltration of leucocytes in tumor tissue</measure>
    <time_frame>Day 0</time_frame>
    <description>Histochemical method with a panel of Ab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Number of adverse events, ECOG status)</measure>
    <time_frame>After Day 0 until the end of the study (Month 3, Month 6, Month 9, Month 12, Month 15, Month 18,Month 21, Month 24, Month 30, Month 36, Month 42, Month 48, Month 54 and Month 60)</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colon Adenocarcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tissu and blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with colon adenocarcinoma treated by surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 or more.

          2. Affiliation to a social security scheme

          3. Diagnosis of a colon adenocarcinoma.

          4. Patient have signed and dated consent of the study before undertaking procedures
             related to the study.

        Exclusion Criteria:

          1. Patients under guardianship / curatorship

          2. Following Situations

               -  Persons unable to understand, read and / or sign an informed consent

               -  Patient with the following functions: investigator or co-investigator, research
                  assistant, pharmacist, study coordinator or having any involvement in the study

               -  Uncooperative person or potentially non-compliant for the study and its
                  procedures with predictable difficulties regular monitoring of over 1 year.

               -  No affiliation to a social security scheme, a universal medical coverage or any
                  similar plan.

          3. Pregnant or lactating women.

          4. Patients with HIV seropositivity.

          5. Rectal tumor location.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Allez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Saint Louis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthieu Allez, MD, PhD</last_name>
    <phone>+33 1 42 49 95 97</phone>
    <email>matthieu.allez@aphp.fr</email>
  </overall_contact>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

